EpiPredict
ML-powered identification of pHLA off-targets for TCR-mimic antibodies
11.12.2025
We are excited to share a major milestone for our company. Our EpiPredict machine learning platform for genome wide pHLA off target prediction has been published in mAbs.
EpiPredict delivers a new level of confidence for safety assessment in TCR like drug modalities and provides a powerful solution for developers of T cell receptor mimic (TCRm) antibodies. By enabling highly specific and data driven identification of off target risks at unprecedented scale and precision, EpiPredict sets a new industry standard for next generation immunotherapy safety analytics.
This publication reinforces our commitment to shaping the future of targeted immune therapies with technologies that enhance predictability, reduce development risk, and accelerate innovation.